Wizr delivers AI-native solutions that transform how pharma organizations manage compliance, regulatory affairs, safety, and commercial execution. Our solutions automate complex workflows end-to-end, with built-in governance, traceability, and optional human verification – enabling speed, accuracy, and regulatory confidence at scale.
Wizr modernizes quality and compliance operations through AI-driven solutions for deviations, CAPAs, SOPs, audits, inspections, and validation. Intelligent workflows automate execution while maintaining full traceability, audit readiness, and risk visibility — with human review available at defined control points.
Today, batch record review in pharma manufacturing is a largely manual process, taking 3 to 5 days per batch, tying up senior QA resources and creating release bottlenecks that compound across high-volume lines. Subtle out-of-trend patterns go undetected, semi-digital records introduce transcription errors, and quality issues surface only after batch completion, driving costly investigations and delays.
Wizr’s AI-powered solution transforms this process from days to minutes.
Rather than sampling, the system reviews 100% of batch record entries, flagging every out-of-spec value, missing signature, and calculation discrepancy in real time. Agents continuously monitor parameters across batches, catching drift before it escalates into a formal deviation. When exceptions do occur, the system auto-generates a first draft of the investigation narrative, shifting your QA team’s role from writing to reviewing and approving.
Beyond individual batches, cross-site trend analytics surface recurring quality issues and systemic root causes, enabling a genuine culture of continuous improvement.
The expected business impact is significant:
For most pharma organizations, CAPA management is a persistent pain point. With average open times of 6 to 9 months, backlogs grow faster than what teams can resolve, and regulators notice. Root cause analysis quality varies widely across sites and individuals, the same problems recur in different forms, and writing inspection-ready narratives demands significant expertise. The result is that CAPA backlogs are consistently among the most common FDA 483 observations.
Wizr brings AI-driven intelligence to every stage of the CAPA lifecycle.
The system analyzes your complete history of deviations, complaints, and prior CAPAs to surface probable root causes, with cited evidence, real-time rather than days. Corrective action recommendations are drawn from successfully closed CAPAs across your own organization, turning institutional knowledge into a structured, searchable resource rather than leaving it locked as an individual expertise.
Critically, the system does not stop at closure. An automated effectiveness check monitors post-closure data and flags any re-emergence of the root cause before final sign-off, ensuring CAPAs are genuinely resolved rather than just administratively closed. Audit-ready narratives are auto-drafted with full traceability to source deviations, risk classifications, and applicable regulatory requirements.
The expected outcomes address both regulatory and operational priorities:
Wizr enables AI-powered regulatory intelligence that continuously monitors global authorities and maps changes to product portfolios. Impact analysis, dossier updates, and submission preparation are automated across regions, delivering faster filings, clearer regulatory insight, and inspection-ready documentation with governed approval workflows.
For generic pharma companies, keeping pace with Reference Listed Drug label updates is a legal obligation. Every change across FDA DailyMed, EMA EPAR, PMDA, and 20+ other global portals must be tracked and mirrored. Yet today, most teams do this manually: comparing full PDFs portal by portal, several hours per drug, with no structured way to quickly identify what actually changed. A single missed Boxed Warning update can trigger serious regulatory and liability consequences.
Wizr automates this surveillance entirely, across 30+ global health agencies simultaneously.
The Agent performs daily scans of all your RLDs and delivers alerts within 24 hours of any change being published, eliminating the risk of a missed update. Rather than providing teams with a raw PDF to decode, Wizr provides an AI-generated delta view that shows exactly what changed, which section was affected, and how severe the change is, distinguishing a routine update from a critical Boxed Warning.
Every detected change and notification is logged with a full timestamp, creating inspection-ready audit evidence available on demand.
The operational and compliance impact is clear:
In today’s competitive pharma landscape, a rival securing a broader indication or an earlier approval in a key market can immediately reshape your commercial and regulatory strategy. Yet most organizations find out weeks too late. Commercial, Regulatory, and BD teams each need competitor approval data, but very few own it centrally, leading to duplicated efforts and inconsistent intelligence. Manually monitoring 20 to 50+ health authorities per therapy area is beyond team capacity, and approvals from countries like Japan, Brazil, China etc. are routinely missed because they are published in local languages.
Wizr’s Competitor Approval Tracker Agent consolidates global competitor approval intelligence into a single platform, serving three teams at once.
Every week, teams receive a curated digest of all competitor approvals in their therapy areas, covering approval date, indication scope, conditions, and the approving agency. Approvals from non-English authorities such as PMDA, ANVISA, and NMPA are automatically translated and summarized in plain English, eliminating a persistent blind spot for global teams.
A built-in label benchmarking feature allows teams to compare a competitor’s approved indication scope directly against their own label in seconds, making competitive gap analysis fast and defensible. For high-priority assets, same-day alerts notify the relevant teams the moment a competitor product is approved anywhere in the world, ensuring no strategic surprise goes undetected.
The business case is compelling:
Regulatory submissions are among the most resource-intensive activities in pharma. Drafting eCTD Module 3 and 4 alone consumes 16 to 20 weeks of experienced medical writer time per submission. Coordinating thousands of documents across Modules 1 through 5, managing version control across CROs and internal teams, and meeting region-specific requirements for multiple markets creates enormous logistical complexity. When technical errors such as broken hyperlinks, wrong file formats, or missing sections reach the FDA or EMA gateway, the cost is a further 2 to 4 week delay at a point when speed to approval matters most.
Wizr eCTD Studio transforms the submission process through an orchestrated Human-in-the-Loop publishing workflow powered by an Army of specialized AI agents working synchronously across the entire eCTD lifecycle. Rather than relying on fragmented manual processes, dedicated agents continuously collaborate to author, collate, classify, cross-reference, validate, translate, and assemble submission-ready dossiers while maintaining complete traceability and regulatory oversight.
The system drafts eCTD narrative sections directly from your existing source documents, including clinical study reports, preclinical summaries, and CMC data, reducing authoring time by up to 70%. Module assembly is automated with real-time compliance checks against eCTD specifications and region-specific Module 1 requirements across 60+ countries, ensuring multi-market submissions are built correctly from the start.
Before a single file is uploaded, a pre-submission technical validation suite catches every gateway error, including broken hyperlinks, missing files, and formatting violations, eliminating the submission delays that derail timelines at the final stage. A cross-reference integrity engine then verifies every table, figure, and citation across all five modules, ensuring nothing reaches the reviewer out of order.
The outcomes directly address the cost and timeline pressures of regulatory submissions:
Wizr modernizes quality and compliance operations through AI-driven solutions for deviations, CAPAs, SOPs, audits, inspections, and validation. Intelligent workflows automate execution while maintaining full traceability, audit readiness, and risk visibility — with human review available at defined control points.
Wizr modernizes quality and compliance operations through AI-driven solutions for deviations, CAPAs, SOPs, audits, inspections, and validation. Intelligent workflows automate execution while maintaining full traceability, audit readiness, and risk visibility — with human review available at defined control points.
Wizr modernizes quality and compliance operations through AI-driven solutions for deviations, CAPAs, SOPs, audits, inspections, and validation. Intelligent workflows automate execution while maintaining full traceability, audit readiness, and risk visibility — with human review available at defined control points.
Wizr modernizes quality and compliance operations through AI-driven solutions for deviations, CAPAs, SOPs, audits, inspections, and validation. Intelligent workflows automate execution while maintaining full traceability, audit readiness, and risk visibility — with human review available at defined control points.
All Wizr solutions support configurable human-in-the-loop verification for regulatory, quality, and safety-critical workflows – ensuring accountability, compliance confidence, and enterprise adoption without slowing automation.
Explore our case studies to see how Wizr is driving transformative change for enterprises with cutting-edge Enterprise Generative AI Solutions.
Wizr delivers production-ready AI systems – automate operations, accelerate software delivery by 50%, & scale intelligence enterprise-wide. Let’s build yours.
